Vitamin B Therapy for Hyperlactatemia

NCT ID: NCT00031057

Last Updated: 2011-02-28

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: NA
• Total Enrollment: 225 participants
• Study Classification: INTERVENTIONAL

Brief Summary

The purpose of this study is to see if vitamin B can treat mild hyperlactatemia (a higher than normal level of lactate in the blood) in patients who take nucleoside reverse transcriptase inhibitors (NRTIs).

Hyperlactatemia is a potentially life-threatening condition that can be associated with NRTI therapy. A lack of vitamin B may be related to the development of hyperlactatemia. However, no studies have been done to evaluate this. This study proposes that high doses of vitamin B may bring elevated lactate levels back to normal among patients taking NRTIs.

Detailed Description

Hyperlactatemia, with or without lactic acidosis, is a potentially life-threatening condition that appears to be associated with NRTI therapy. The natural history of lactate elevation as a complication of NRTI therapy is not clearly understood; however, some patients receiving these therapies experience a progressive increase in lactate to symptomatic levels. Deficiencies in thiamine (vitamin B1) and riboflavin (vitamin B2) have been implicated as cofactors in producing hyperlactatemia and lactic acidosis in NRTI-treated patients. A nontoxic intervention that could prevent or reverse advancing lactic acidosis and preserve NRTI use would be highly desirable. To date, no controlled studies have been done to examine the potential role of dietary intake, B vitamin deficiency, and B vitamin therapy on the pathogenesis and clinical course on NRTI-associated lactic acidosis. The hypothesis proposed is that high-dose vitamin B treatment can normalize elevated lactate levels among NRTI-exposed individuals with moderately elevated lactate levels.

This study consists of 2 steps: Step 1 (screening) and Step 2 (treatment). Patients are screened during Step 1 for sustained hyperlactatemia and Step 2 eligibility. Patients with sustained hyperlactatemia but no symptoms that indicate high risk of progression to lactic acidosis and with no plans to change existing NRTI-containing antiretroviral therapy may enter Step 2. A fasting, nonexercise, venous lactate level is obtained at Step 2 entry for use as a baseline measurement, and every patient receives high-dose oral vitamin B1 and B2 therapy for 4 weeks. Fasting, nonexercise, venous lactate levels are measured at Weeks 1, 2, and 4 to observe the kinetics of changes in lactate levels on study treatment.

Conditions

HIV Infections

Keywords

Administration, Oral; Blood; Reverse Transcriptase Inhibitors; Riboflavin; Thiamine; Vitamin B Complex; Lactic Acid

Study Design

• Primary Study Purpose: TREATMENT

Interventions

Thiamine hydrochloride

Intervention Type: DRUG

Riboflavin

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Patients may be eligible for this study if they:

• Are at least 13 years old.
• Give written informed consent. Patients less than 18 years old must have written informed consent of a parent or guardian.
• Are HIV-infected.
• Have been using anti-HIV therapy containing an NRTI for at least 4 weeks before study entry and have no plan to change their anti-HIV treatment during the study.
• Fulfill at least 1 criterion listed in protocol indicating an elevated venous lactate measurement.

Exclusion Criteria

Patients may not be eligible for this study if they:

• Have inflammation of the pancreas 30 days before study entry.
• Have other medical conditions that may result in elevated lactate levels.
• Are pregnant or breast-feeding.
• Started experiencing certain symptoms within 30 days prior to study entry that might be due to hyperlactatemia.
• Have used metformin within 30 days prior to study entry.
• Have used high-dose vitamin supplements containing vitamin B1 (thiamine) and/or vitamin B2 (riboflavin) within 30 days prior to study entry.
• Have used certain dietary supplements within 30 days prior to study entry.
• Use chemotherapy.
• Are receiving any unknown therapies or medications.
• Are allergic or sensitive to the study drug.
• Had an illness within 30 days before study entry that, in the opinion of the investigator, would interfere with the study.
• Use drugs or alcohol that, in the opinion of the investigator, would interfere with the study.

• Minimum Eligible Age: 13 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institute of Allergy and Infectious Diseases (NIAID)

NIH

Sponsor Role: lead

Principal Investigators

Christopher Pilcher

Role: STUDY_CHAIR

Locations

Beth Israel Med Ctr

New York, New York, United States

Univ of North Carolina

Chapel Hill, North Carolina, United States

Case Western Reserve Univ

Cleveland, Ohio, United States

Countries

United States

References

Wohl DA, Pilcher CD, Evans S, Revuelta M, McComsey G, Yang Y, Zackin R, Alston B, Welch S, Basar M, Kashuba A, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H, Koletar SL; Adult AIDS Clinical Trials Group A5129 Team. Absence of sustained hyperlactatemia in HIV-infected patients with risk factors for mitochondrial toxicity. J Acquir Immune Defic Syndr. 2004 Mar 1;35(3):274-8. doi: 10.1097/00126334-200403010-00008.

Reference Type: RESULT

PMID: 15076242 (View on PubMed)

Other Identifiers

AACTG A5129

Identifier Type: -

Identifier Source: secondary_id

ACTG A5129

Identifier Type: -

Identifier Source: org_study_id